 |
|
|
| Internet Search |
|
Stock Search |
|
|
|
|
|
APHTON CORP, (APHT) Stock Rating Learn More
| Our Overall Rating on APHTON CORP, APHT is Not Available | | Aphton Corporation, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products based on its proprietary immunization and monoclonal antibody technologies for the treatment of cancer and gastrointestinal diseases. Its lead product candidate is G17DT, an immunotherapeutic, which completed two phase III clinical trial, for the treatment of pancreatic cancer. G17DT also completed one phase II clinical trial for the treatment of gastric cancer and one phase II clinical trial for the treatment of colorectal cancer. In addition, Aphton is developing antigastrin immunogen for the treatment of gastroesophageal reflux disease, also known as severe heartburn. The company, through its subsidiary, Igeneon AG, develops active and passive cancer immunotherapies. Igeneons lead product candidate is IGN101, a cancer vaccine in a Phase II/III clinical trial. Aphton has strategic alliances with Sanofi-Aventis for treating gastrointestinal system and other cancers with G17DT in the United States, Canada, and Europe; with Daiichi Pure Chemicals Co., Ltd. for the development, manufacturing, and commercialization of gastrin-related diagnostic kits; and with Xoma (US) LLC. for the treatment of gastrointestinal and other gastrin-sensitive cancers. The company is headquartered in Miami, Florida. | | Our Not Available Rating on APHT was issued on 11/22/2008 |
APHTON CORP Technical Rating
|
|
|
|
